Země: Spojené státy
Jazyk: angličtina
Zdroj: NLM (National Library of Medicine)
DORIPENEM (UNII: BHV525JOBH) (DORIPENEM - UNII:BHV525JOBH)
Shionogi Inc.
DORIPENEM
DORIPENEM 500 mg in 10 mL
INTRAVENOUS
PRESCRIPTION DRUG
DORIBAX ® (doripenem for injection) is indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros . DORIBAX ® (doripenem for injection) is indicated as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , and Acinetobacter baumannii . To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX ® and other antibacterial drugs, DORIBAX ® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility infor
DORIBAX ® is supplied as single use type 1 clear glass vials containing 250 mg or 500 mg (on an anhydrous basis) of sterile doripenem powder. Vials are packaged individually and in cartons containing 10 vials. Storage of DORIBAX ® vials DORIBAX ® should be stored at 25°C (77°F); excursions permitted to 15°–30°C (59° to 86°F) [refer to USP controlled room temperature].
New Drug Application
DORIBAX- DORIPENEM POWDER, FOR SOLUTION SHIONOGI INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USEDORIBAX SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DORIBAX . DORIBAX (DORIPENEM FOR INJECTION), FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 2007 INDICATIONS AND USAGE DORIBAX is a penem antibacterial indicated in the treatment of the following infections caused by designated susceptible bacteria: Complicated intra-abdominal infections ( 1.1) Complicated urinary tract infections, including pyelonephritis ( 1.2) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX and other antibacterial drugs, DORIBAX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.3) DOSAGE AND ADMINISTRATION 500 mg every 8 hours by intravenous infusion administered over one hour for patients ≥18 years of age. ( 2.1) Dosage in patients with impaired renal function ( 2.2) CRCL (ML/MIN) RECOMMENDED DOSE OF DORIBAX > 50 No dosage adjustment necessary ≥ 30 to ≤ 50 250 mg IV (over 1 hour) every 8 hours > 10 to < 30 250 mg IV (over 1 hour) every 12 hours DOSAGE FORMS AND STRENGTHS 250 mg single use vial or 500 mg single use vial of sterile doripenem powder for reconstitution ( 3) CONTRAINDICATIONS Patients with known serious hypersensitivity to doripenem or to other drugs in the same class or patients who have demonstrated anaphylactic reactions to beta-lactams ( 4) WARNINGS AND PRECAUTIONS Increased mortality in ventilator-associated bacterial pneumonia patients. Doripenem is not indicated for ventilator- associated bacterial pneumonia ( 5.1) Serious hypersensitivity (anaphylactic) reactions have been reported with carbapenems and other beta-lactams ( 5.2) Seizures have been reported with carbapenems, including doripenem ( 5.3) It has been shown that co-administration of DORIBAX with valproic acid reduces the serum concentration of valproic acid. Patient Přečtěte si celý dokument